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Background: Prebiotics are food ingredients, usually non-digestible oligosaccharides, that are selectively fermented by
populations of beneficial gut bacteria. Endoxylanases, altering the naturally present cereal arabinoxylans, are commonly
used in the bread industry to improve dough and bread characteristics. Recently, an in situ method has been developed
to produce arabinoxylan-oligosaccharides (AXOS) at high levels in breads through the use of a thermophilic
endoxylanase. AXOS have demonstrated potentially prebiotic properties in that they have been observed to lead to
beneficial shifts in the microbiota in vitro and in murine, poultry and human studies.
Methods: A double-blind, placebo controlled human intervention study was undertaken with 40 healthy adult volunteers
to assess the impact of consumption of breads with in situ produced AXOS (containing 2.2 g AXOS) compared to
non-endoxylanase treated breads. Volatile fatty acid concentrations in faeces were assessed and fluorescence in situ
hybridisation was used to assess changes in gut microbial groups. Secretory immunoglobulin A (sIgA) levels in saliva were
also measured.
Results: Consumption of AXOS-enriched breads led to increased faecal butyrate and a trend for reduced iso-valerate and
fatty acids associated with protein fermentation. Faecal levels of bifidobacteria increased following initial control breads
and remained elevated throughout the study. Lactobacilli levels were elevated following both placebo and AXOS-breads.
No changes in salivary secretory IgA levels were observed during the study. Furthermore, no adverse effects on
gastrointestinal symptoms were reported during AXOS-bread intake.
Conclusions: AXOS-breads led to a potentially beneficial shift in fermentation end products and are well tolerated.
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Dietary approaches to manipulate the human gut micro-
biota have long been used as an approach to improve host
health. The aim of probiotic and prebiotic inclusions into
the diet are to increase beneficial gut bacteria and their
activities, thus generating benefits to human health. These
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reproduction in any medium, provided the orpathogen inhibition [1], an improved tolerance to lactose
[2], toxins [3] and cholesterol reduction [4], vitamin syn-
thesis [3], improved mineral bioavailability [5], potential
protection from bowel cancer [6-8], reduced symptoms of
irritable bowel syndrome [9], improved digestion, gut
function [10] and immune regulation [11].
Much interest in the development of prebiotics has been
focused on non-digestible oligosaccharides. The prebiotic
effects of fructooligosaccharides (FOS), inulin [12-15] and
galactooligosaccharides (GOS) [9,16] have been extensively
evidenced by changes in gut microbial composition throughLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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charides on the market, the development of novel forms of
oligosaccharides as prebiotics is required to enable incorp-
oration into more versatile food forms. In the bakery
industry, the enzyme endoxylanase has been used for more
than 30 years. Endoxylanase can improve dough
consistency by enhancing strength of the gluten network
[17]; improving bread volume and bread crumb structure
through solubilising arabinoxylans (AX) [18]. Furthermore,
AX have a beneficial influence on the bread-making process
[18]. By using the appropriate type and dose of endoxyla-
nases during bread-making, naturally present AX fibres can
be converted into arabinoxylan-oligosaccharides (AXOS)
fragments, with an average degree of polymerization (avDP)
between 5 and 50. This provides an in situ production
approach that may be considered as an alternative to
straightforward fortification [18,19].
AXOS have shown prebiotic potential [20], leading to
a potentially beneficially shift in gut bacteria in in vitro
intestinal models [21,22], poultry studies [23] and
human studies [24]. In intervention studies with poultry,
it was observed that AXOS added to the diet dose de-
pendently lead to reduced Salmonella numbers following
infection when compared to a control group [25]. The
positive impact of AXOS on intestinal fermentation was
observed in a human study, whereby a daily intake of
10.0 g AXOS added to the diet of healthy persons was
well-tolerated and promoted bifidobacterial growth
while suppressing the excretion of urinary p-cresol, a po-
tentially harmful metabolite of protein fermentation
[24]. Additionally, Cloetens et al. [26] indicated that con-
sumption of AXOS added to the diet at doses as low as
2.2 g was associated with a beneficial shift from urinary
to fecal N excretion.
In vitro AXOS fermentation led to decreases in the po-
tentially negative proteolytic products (phenol and p-cresol)
in distal regions of a colonic simulator model, whilst in-
creasing levels of short chain fatty acids [22]. A potentially
favourable metabolic shift in fermentation was also
observed in human volunteers [26]. Furthermore, the fer-
mentation of AXOS has been linked to increased butyrate
levels in rat studies [27]. Butyrate is a major energy source
for intestinal epithelial cells and is considered to be a poten-
tial anti-cancer agent through its ability to stimulate apop-
tosis [28]. As such, its increase is largely regarded to be of
benefit to the host.
Recently, there has been interest in the ability of the
bacteria in the intestine to influence host immune func-
tions, including through an up-regulation of immuno-
globulins (Ig), that aid the fight against infection. It has
recently been observed that probiotics can lead to
increased salivary secretory IgA levels [29].
The current human trial was conducted to assess
effects of the consumption of breads with in situproduced AXOS on the faecal microbiota and their fer-
mentation products, such as faecal volatile fatty acid
concentrations. A secondary aim was to determine
whether AXOS-breads could impact on salivary
secretory IgA concentrations. Volunteer diaries were
collected to assess gastrointestinal effects such as toler-
ance, changes in bowel habit and food consumption and
also emotional changes.
Methods
Production and characterisation of the investigational
products
Refined wheat endosperm flour bread without in situ
produced AXOS (control bread) was prepared by mixing
25000 g wheat flour (white) (Surbi, Dossche Mills &
Bakery, Deinze, Belgium) with 500 g (2%) of salt, 500 g
of baker’s yeast (Algist Bruggeman, Gent, Belgium),
500 g of endoxylanase-free bread improver mix (Puratos
Group, Groot-Bijgaarden, Belgium), 500 g of gluten
(Syral, Aalst, Belgium) and 14500 ml of water. Wheat/
rye bread without in situ produced AXOS (placebo
bread) was prepared by mixing 18750 g wheat flour
(white) with 4375 g rye whole meal (Type 1740; Plange
Mühle, Düsseldorf, Germany), 1875 g rye bran
(Paniflower, Gent, Belgium), 500 g of salt, 500 g of
baker’s yeast, 500 g of endoxylanase-free bread improver
mix, 500 g of gluten and 15525 ml of water.
Wheat/rye bread with in situ produced AXOS (AXOS-
bread) was prepared as placebo except that the water
was reduced (15500 ml) and an endoxylanase prepar-
ation with an activity of 42000 Units/g (25 g) (Puratos
Group, Groot-Bijgaarden, Belgium) was added. Major
constituents of the breads are shown in Table 1.
After mixing, the dough was divided in pieces of 820 g
each, rounded manually and allowed to rise at room
temperature for 20 min, followed by mechanical
moulding, panning and fermentation proofing (90 min
at 35 °C and 95% relative humidity). Doughs were baked
in a hot air oven at 230 °C for 35 min. Two and a half
hours after baking, the breads were sliced, packaged in
polypropylene bags in rations of 180 g per pack, and fro-
zen at −20 °C until consumption by the volunteers.
The breads were labelled by colours, therefore volun-
teers and investigators were unaware which bread
treatment was issued.
Compositional analyses of breads
Bread slices from the middle of the loaf were dried (12 h
at 105 °C) then cooled to room temperature in an exsic-
cator for 1 h. The dried bread was homogenised to yield
a powder. For characterisation of the AX population,
aqueous extracts of breads dried and ground (2 g) was
mixed with water (20 ml) and Termamyl 120 L (120 μl)
(Novozymes, Bagsvaerd, Denmark), the Termamyl was
Table 1 Major constituents of the breads used in the
study
Wheat flour Rye flour Rye bran Endoxylanase
Control bread 100% 0% 0% none
Placebo bread 75% 17.5% 7.5% none
AXOS-bread 75% 17.5% 7.5% 42000 units/g
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destroy possible enzyme activities within, other than
amylase. The suspension was incubated whilst shaking
(37 °C, 30 min) and subsequently centrifuged (3000 x g,
4 °C, 15 min). The supernatant was stored at −20 °C
until further analysis.
Total hydrolysable carbohydrate content of breads and
total and reducing end saccharide contents of aqueous
extracts thereof were measured by gas chromatography
(GC) of alditol acetates obtained after acid hydrolysis, re-
duction and acetylation of the resulting monosaccharides
as described by Courtin et al. [30]. Alditol acetates (1.0 μL)
were separated on a Supelco SP-2380 polar column (30 m,
0.32 mm i.d.; 0.2 ím film thickness) (Supelco, Bellefonte,
PA) in an Agilent chromatograph (Agilent 6890 series,
Wilmington, DE) equipped with autosampler, splitter injec-
tion port (split ratio 1:20), and flame ionization detector.
The carrier gas was helium. Separation was at 225 °C, and
injection and detection were at 270 °C. The coefficient of
variation of the results of this analysis was< 5,0%.
The total AX content of bread was calculated as
described by Damen et al., 2012, [31] using concentra-
tions of arabinose, galactose, xylose. As the anhydroxy-
lose and anhydroarabinose units in AX are hydrated
upon hydrolysis, a correction for this molecular mass
shift has been incorporated in the calculations. Total AX
in baseline/control, placebo and AXOS-bread were 2.0,
4.2 and 4.2% dry matter (dm), respectively. Endoxylanase
treatment in AXOS-bread resulted in an AXOS level of
2.0% (dm) with an avDP of 18 while baseline/control
and placebo bread had a water-extractable AX content
of 0.6 and 0.9% (dm) with an avDP of 157 and 174, re-
spectively. Seven slices of AXOS-bread (180 g/d)
resulted in an intake of 2.2 g AXOS/day.
Subjects
Volunteers were aged 18–55 years, BMI: 18.5-30 kg/m²,
of good general health and free of chronic diseases such
as gastrointestinal illness and were required to avoid
consumptions of any pharmaceuticals active on the
gastrointestinal tract, including antibiotics, for at least
6 months before the study began. Volunteers were asked
to refrain from any consumption of prebiotics and pro-
biotics or laxatives within 1 month of the start and
during the trial. Volunteers were excluded if pregnant or
lactating.Volunteers with a history of alcohol or drug abuse and
current smokers were excluded as were those that had
taken experimental drugs or been involved in experi-
mental drug studies within the last month and those
regularly consuming excessive alcohol (weekly more
than 21 units/wk (male), 14 units/wk (female)). Volun-
teers were required to not have taken part in pre- and
probiotic studies in the previous 3 months. Major sur-
gery and physical or mental conditions that might effect
participation in the study were also used as exclusion
factors.
Furthermore, volunteers with severe allergy to foods
including celiac disease; severe abnormal drug reactions,
chronic gastroenterological complaints, those on calorie
restricted or other special diets (e.g. Atkins diet, mon-
tignac diet) 6 weeks prior to the start of the study, those
who had been vaccinated against with the current sea-
son’s influenza and AH1N1 flu, those with severe aller-
gies, asthma and dermatitis and those who had had
colonic irrigation within the previous 3 months were
excluded from the study.
Forty-four healthy adults, 22 males and 22 females,
were recruited from the local Reading area (UK) for par-
ticipation in this study. Four subjects dropped out
during the first feeding period, 3 due to the bread quan-
tity, 1 to altered travel plans. A final volunteer dropped
out (male) mid-way through the study for personal rea-
sons. For analysis purposes, 40 volunteers were included,
1 treatment was completed by the final drop-out volun-
teer for the remaining time-points missing data was
omitted from the calculations using Minitab 16 (Lead
technologies inc., North Carolina, USA). The final study
group of 40 volunteers consisted of 20 males and 20
females. Their mean age was 31.4 years (± 8.9) and aver-
age BMI was 23.3 kg/m2 (± 2.8). The Research Ethics
Committee of The University of Reading approved the
study and it was conducted in accordance with the Hel-
sinki Declaration of 1975 as revised in 1983.
Study design
The dietary intervention study was a randomised,
double-blind, placebo controlled cross-over trial. The
dietary intervention was split into 5 periods including
AXOS-treatment and placebo periods which were sepa-
rated by 3 control periods, each period consisting of
21 days (Figure 1). The volunteers were randomly allo-
cated into 1 of the 2 groups. Group 1 (n 20, 10 males
and 10 females, Age 31.8 ± 9.9 years, BMI 23.2 ± 2.79 kg/
m²) consumed control breads for the first period, then
consumed AXOS-breads (treatment 1) for the following
21 days, and thereafter control breads for a further
21 days as a washout period. Placebo breads (treatment
2) were consumed for 21 days, followed by 21 days
washout period of control bread. Meanwhile, Group 2 (n
Figure 1 Cross-over trial design.
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23.2 ± 2.97 kg/m²) underwent the same control and
treatment periods as Group 1, but they received placebo
breads when the AXOS-breads were consumed by
Group 1 and vice versa.
Volunteers were required to consume 7 slices of bread
each day of the trial (total 180 g/day). Faecal and saliva
samples were collected from each volunteer at 6 differ-
ent time points, the first sample was prior to any inter-
vention this was the baseline sample. Thereafter samples
were taken post intervention period and post washout
periods these sample periods are indicated in Figure 1.
Volunteer diaries
To record gastrointestinal symptoms, volunteers kept
diaries on a daily basis during the study. The diaries
detailed stool frequency and consistency, abdominal
pain, intestinal bloating and flatulence. Emotional
changes including energetic status, happiness, alertness
and stress levels were recorded as compared to normal.
Lastly, concomitant medication, adverse events and fail-
ure to consume breads was also documented by the
volunteers. A food frequency diary was completed by the
volunteers over 4 consecutive days during the study per-
iods (one day of which was during a weekend). Daily nu-
tritional intake was calculated using Dietplan 6
(Forestfield software, West Sussex, United Kingdom).
Sample collection and preparation of faecal sample
Freshly voided faecal samples were collected in plastic pots,
placed in an anaerobic workstation (H2:CO2:N2, 10:10:80
by volume at 37 °C) (Don Whitley Scientific, West York-
shire, UK) and processed within 2 h of voiding. Samples
were diluted 1:10 (w:w) in phosphate-buffered saline (PBS,
0.1 M; pH 7.4), then homogenised using a stomacher (460
paddle beats/min) for 2 min. One ml of this was taken, cen-
trifuged for 10 min at 13,000 x g at room temperature and
the supernatant retained for volatile fatty acid analysis.
Samples were vortexed with 3 mm glass beads (VWR) for
30 s before being centrifuged at 400 x g for 2 min at roomtemperature. The supernatant (375 μl) was fixed in 4% (w:
v) (1125 μl) paraformaldehyde for 4 h at 4 °C. To wash the
cells out of paraformaldehyde, samples were centrifuged at
13000 x g in 1 ml PBS for 5 min at room temperature and
this centrifugation was repeated two more times, then sam-
ples were re-suspended in 150 μl PBS and stored in ethanol
(1:1 by v:v) at −20 °C for fluorescence in situ hybrdidsation
(FISH).
Enumeration of faecal microbial population
FISH, using fluorescently labelled 16 S rRNA targeted
oligonucleotide probes (Sigma-Aldrich, Steinheim, Ger-
many) labelled at the 5’ end with the fluorescent dye
Cy3, was used for bacterial enumeration of the faecal
samples. The details of probes used in this study and hy-
bridisation conditions are in Table 2. The FISH proced-
ure was conducted as by Martìn-Peláez et al., 2008 [32].
Faecal volatile fatty acid analysis
Volatile fatty acids (VFA) were converted into tertbutyl-
dimethylsilyl derivatives and analysis performed using
the extraction procedure of Richardson et al., 1989 [42].
A HP 5890 series II GC system (Hewlett Packard, Palo
Alto, Calif.) with a fused silica dimethyl polysiloxane
10 m, 0.18 mm ID, 0.20 μm df (Crossbond, Restek, Bel-
lefonte, PA) was used. Injector and detector tempera-
tures were 275 °C with the column temperature
programmed from 60 °C for 3 min to 150 °C at 10 °C/
min. Helium was the carrier gas. Injections of 1 μl vol-
ume were made by an autosampler. The response factors
of compounds were calculated compared to the internal
standard solution. This was used along with the cali-
brated compounds to ascertain concentrations. To main-
tain calibration, at every 15 samples, an external
standard solution with known concentrations of volatile
fatty acids was injected.
Collection of saliva samples and sIgA assessment
Volunteers arrived at the Department following 30 min
of fasting and no brushing of teeth. Volunteers were
Table 2 Hybridisation conditions for oligonucleotide probes used in this study
Probe
name




Temperature (°C) Bacteria covered
Hybridisation Washing
Ato291 GGTCGGTCTCTCAACCC Lysozyme 0 50 50 Atopobuim- Coriobacterium [33]
Bac303 CCAATGTGGGGGACCTT None 0 46 48 Bacteroides – Prevotella [34]
Bif164 CATCCGGCATTACCACCC Lysozyme 0 50 50 Bifidobacterium spp [35]
Chis150 TTATGCGGTATTAATCTYCCTTT None 0 50 50 Clostridium histolyticum-
Clostridium perfringens
[36]
Erec482 GCTTCTTAGTCARGTACCG None 0 50 50 Eubacterium rectale-
Clostridium coccoides
[36]
Lab158 GGTATTAGCAYCTGTTTCCA Lysozyme 0 50 50 Lactobacillus- Enterococcus [37]
Eco1531 CACCGTAGTGCCTCGTCATCA None 35 37 37 Escherichia coli [38]
Rrec584 TCAGACTTGCCGYACCGC None 0 50 50 Roseburia and Eubacterium
rectale
[39]
Fprau645 CCTCTGCACTACTCAAGAAAAAC Lysozyme 15 46 48 Faecalibacterium prausnitzzi [40]
EUB338{ GCTGCCTCCCGTAGGAGT None 35 46 48 Total bacteria 1 [41]
EUB338II{ GCAGCCACCCGTAGGTGT None 35 46 48 Total bacteria [41]
EUB338III{ GCTGCCACCCGTAGGTGT None 35 46 48 Total bacteria [41]
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Amsterdam, Netherlands) in which to passively dribble
for 2 min. Saliva samples were centrifuged at 13000 x g
for 5 min at room temperature and the supernatant was
stored at −20 °C. The sIgA concentration was assessed
by an enzyme-linked immunosorbet assay (ELISA) kit
according to the manufacturer’s instructions (Immun-
diagnostik AG, Bensheim, Germany). Absorption was
detected at 450 nm against 630 nm using an ELISA
reader (Tecan Genios, Switzerland). A range of IgA stan-
dards were used in every assay, for which a calibration
curve was constructed, to quantify the sIgA amount
within the samples.
Statistical analyses
Bacterial numbers were statistically evaluated after trans-
formation to log counts using Microsoft Office Excel 2007
(Washington, USA). Target bacterial groups, fermentation
characteristics, salivary sIgA and faecal pH were grouped
according to which treatment was consumed, then analysed
using a paired t-test Minitab 16 (Lead technologies, North
Carolina, USA). The bacteriology data was observed to fol-
low a normal distribution pattern, except for in the case of
the E. coli group analysis. Furthermore, the VFA data also
followed non-normal distribution, therefore Wilcoxon
signed rank was used for these analyses. In order to con-
duct the Wilcoxon signed rank test in a paired manner,
changes in parameter were calculated and compared to a
test-median of 0. Data is reported± standard deviation.
To analyse the volunteer diaries volunteer responses
were assigned scores, for example for with stool
consistency −1 refers to soft; 0 to formed and 1 hard.
These values for each volunteer over the intervention
periods were averaged and paired t-tests used on thesevalues. The dietary diaries were analysed using Dietplan
6 (Forestfield software, West Sussex, UK) during the pla-
cebo and AXOS intervention periods. Results were aver-
aged and compared using a paired t-test. When a value
of P< 0.05 was obtained a change was considered to be
a statistically significant different.
By the use of a statistical power calculation, it was
observed that at significance level of 5% (one-sided) that,
a log change of 0.32 can be detected at a power of 90%
with 39 volunteers. This calculation is based on the as-
sumption that the within patient standard deviation is
0.42, which was as observed by Tuohy et al., 2001 [12].
Results
In terms of faecal bacteriology, consumption of the
initial control breads led to a significant increase in bifi-
dobacteria from baseline (p = 0.0011). The bifidobacteria
levels remained elevated throughout the study (Table 3).
Lactobacilli and bacteroides significantly increased fol-
lowing both placebo (p = 0.018, <0.001) and AXOS-
breads (p = 0.025, 0.050) as compared to pre- treatment
levels. Post-AXOS treatment, bacteroides numbers con-
tinued to rise (p = 0.004) whilst lactobacilli numbers
declined to pre-AXOS treatment levels (p = 0.007).
Bacteria in the E. rectale group, the Roseburia – Eu-
bacterium subgroup and Faecalibacterium prausnitzii
group increased significantly following placebo treat-
ment, compared to pre-placebo treatment (p = 0.003;
0.010 and 0.044 respectively). E. rectale group and bac-
teroides both remained elevated following the post-
placebo treatment washout, so were significantly differ-
ent to pre-placebo treatment (p = 0.001; 0.001). Total
bacteria increased significantly following AXOS treat-
ment (p = 0.038).
Table 3 Faecal bacterial numbers (log10 cells/g faeces) determined by fluorescent in situ hybridisation for forty
volunteers over the trial period during which they were consuming “placebo” or “AXOS” experimental bread products























8.35 ±0.72 8.43 ±0.69 8.07 ±0.64 8.04 ±0.76 a 8.05 ±0.85 a 8.14 ±0.79 8.13 ±0.74 8.14 ±0.57
E. coli 7.20 ±0.39 7.35 ±0.56 7.38 ±0.47 a 7.33 ±0.40 7.34 ±0.45 7.34 ±0.53 7.34 ±0.50 a 7.40 ±0.39 a
Lactobacillus –
Enterococcus




9.73 ±0.24 9.80 ±0.27 9.79 ±0.28 9.84 ±0.34 9.87 ±0.26 a 9.88 ±0.28 a 9.79 ±0.21 9.87 ±0.26 a
E. rectale group 9.96 ±0.27 9.87 ±0.33 9.91 ±0.33 c 10.07 ±0.29 ab 10.08 ±0.29 a b 9.99 ±0.33 10.01 ±0.34 10.08 ±0.32 a
Total bacteria 10.73 ±0.22 10.69 ±0.22 10.70 ±0.25 10.72 ±0.20 10.68 ±0.22 10.72 ±0.18 10.81 ±0.21 b 10.72 ±0.25
Bacteroides 9.54 ±0.32 9.64 ±0.44 9.85 ±0.46 ac 10.07 ±0.25 ab 10.11 ±0.29 a b 9.91 ±0.42 ac 9.99 ±0.34 abc 10.12 ±0.22 a b
Roseburia –
Eubacteria
9.65 ±0.21 9.69 ±0.26 9.57 ±0.44 9.79 ±0.39 ab 9.67 ±0.51 9.74 ±0.27 9.73 ±0.32 9.61 ±0.47
Faecalibacterium
prausnitzii cluster
9.57 ±0.42 9.48 ±0.44 9.53 ±0.40 9.65 ±0.33 b 9.52 ±0.46 9.50 ±0.51 c 9.56 ±0.38 9.67 ±0.41 b
A paired t-test was used to compare bacteria levels at different time points, for E. coli the non parametric Wilcoxon signed rank test was used, as this data did not
follow a normal distribution.
a - different to baseline; b- different to pre-treatment; c- different to washout, (p< 0.05).
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treatment (p = 0.041) (Table 4). Propionate levels were
significantly higher post-AXOS treatment washout com-
pared to pre-AXOS treatment (p = 0.045). Valerate levels
significantly increased following consumption of control
breads (p = 0.008) compared to baseline and remained
elevated throughout all interventions, therefore the val-
erate concentration was significantly greater at pre-
placebo, placebo, pre-AXOS and AXOS treatmentTable 4 Volatile fatty acid (VFA) concentrations (μmol/g faece
and GC analysis for forty volunteers over the trial period dur







Acetate 45.6 ±27.9 47.3 ±21.8 51.1 ±18.8 54
Propionate 17.8 ±13.7 16.5 ±11.1 18.2 ±10.1 19
Butyrate 11.5 ±7.9 13.6 ±9.4 14.9 ±10.1 14
Total acetate, propionate
and butyrate
74.9 ±44.7 77.4 ±37.0 84.2 ±33.3 87
Valerate 1.2 ±1.4 2.3 ±2.3a 2.4 ±2.3a 2.2
Iso-valerate 1.3 ±0.6 1.3 ±1.0 1.5 ±1.3 1.3
Caproate 0.8 ±0.8 0.7 ±0.9 0.9 ±1.3 1.0
Iso-butyrate 1.7 ±0.7 1.6 ±1.2 1.9 ±1.5 1.7
Total valerate, iso-valerate,
caproate and iso-butyrate
4.9 ±2.5 5.8 ±4.5 6.7 ±5.0 6.2
P-values of VFA changes. Wilcoxons signed rank test was used to determine statis
distribution.
a - different to baseline; b- different to pre-treatment; c- different to washout, (p<compared to baseline (p = 0.010, 0.013, 0.004 and 0.017,
respectively). Following AXOS-bread consumption, a
trend for reduced iso-valerate concentration was
observed (p = 0.058).
Furthermore, a trend for increased combined acetate,
propionate and butyrate following AXOS breads com-
pared to pre-AXOS treatment (p = 0.072) and decreased
combined iso-valerate, iso-butyrate, valerate and capro-
ate (p = 0.091) was observed.s) determined by tertbutyldimethylsilyl derivatisation
ing which they were consuming control, placebo or














.2 ±26.4 48.0 ±22.5 46.7 ±22.3 55.1 ±34.5 52.1 ±19.6
.5 ±11.2 17.1 ±10.9 16.1 ±10.9c 17.5 ±10.4 18.8 ±8.6b
.6 ±7.2a 15.0 ±10.1 12.8 ±8.8 16.3 ±12.3ab 14.5 ±7.9
.8 ±6.2 80.2 ±38.3 75.6 ±36.9 88.9 ±52.4 85.4 ±31.6
±1.8a 2.0 ±2.3 2.4 ±1.5a 2.3 ±2.2a 1.7 ±2.0
±1.1 1.7 ±1.1 1.4 ±0.7 1.1 ±1.0 1.7 ±2.0
±1.4 0.8 ±0.8 0.8 ±0.8 0.7 ±0.8 1.1 ±1.4
±1.3 1.8 ±1.2 1.6 ±0.9 1.3 ±1.1 1.8 ±1.3
±4.9a 6.2 ±3.7 6.1 ±2.8 5.4 ±4.2 6.3 ±4.5
tical differences between levels of VFA, as this data did not follow a normal
0.05).
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ing placebo treatment there was an increase in stool
number, compared to pre-placebo treatment (p = 0.049).
Volunteers noted having more energy than normal fol-
lowing the placebo treatment compared to pre-placebo
treatment (p = 0.006) (Table 5).
There were no significant changes in salivary sIgA
concentrations (data not shown) or for volunteer dietary
intakes when consuming the AXOS and placebo treat-
ments (Table 6).
Discussion
A double–blind, placebo-controlled, randomised cross-
over study was undertaken to determine the potential
benefits of AXOS-enriched bread on the gut. Bacteri-
ology within faeces, faecal volatile fatty acid profiles and
concentrations of sIgA in saliva, bowel habit and food
intake of healthy volunteers was monitored throughout
the feeding study.
During the study, 3 volunteers were withdrawn due to
difficulties in eating 180 g bread daily. Based on the vol-
unteer diaries, between 4 to 9 volunteers had difficulty
in taking product in each of the periods. However, the
breads did not lead to adverse symptoms and compli-
ance was excellent with 99.24% of breads issued to the
volunteers consumed. Volunteers were observed to be
maintaining their diets throughout the study, with no
significant changes in energy, protein, carbohydrate,
fibre, non-starch polysaccharide, fat or iron consump-
tion. The observation of increased stool number (stools/
day) and an increased energetic feeling following placebo
treatment (Table 5) was not observed following AXOS
treatment. In the study of Cloetens et al., [24] AXOS
extracted from wheat bran resulted in increased flatu-





No of stools 1.30 ±0.72 1.33 ±0.75 1.43 ±0.76
Abdominal
discomfort score *
0.11 ±0.18 0.10 ±0.16 0.10 ±0.18
bloating score * 0.18 ±0.27 0.18 ±0.24 0.20 ±0.27
flatulence score * 0.52 ±0.53 0.47 ±0.50 0.54 ±0.55
Happy score ** 0.01 ±0.20 0.02 ±0.17 0.02 ±0.16
Alert ** −0.01 ±0.15 −0.01 ±0.09 0.03 ±0.19
Energetic ** −0.07 ±0.26 −0.07 ±0.18 0.01 ±0.14
Stressed ** 0.03 ±0.23 0.02 ±0.15 0.05 ±0.26
Consistency *** 3.67 ±0.79 3.51 ±0.79 3.45 ±0.77
* 0 – none, 1 – mild, 2 – moderate, 3 – severe.
** -1 – less than normal, 0 – normal, 1 – more than normal.
*** Bristol stool scale, 1 = hard, 7 = liquid.
b – significantly different to pre-treatment, (p< 0.05).
P-values of volunteer diary changes. A paired t-test was used to compare volunteAXOS was consumed at a lower dose within bread.
Hence in the current study the AXOS-bread was well-
tolerated.
Following AXOS treatment, a significant increase in
faecal butyrate was observed (Table 4). Such an increase
is regarded to be of benefit to the host, as butyrate is a
major intestinal epithelial cell energy source, associated
with potential anticancer activities observed as reducing
cellular malignancy through stimulation of apoptosis in
malignant cells [28]. Butyrate has also been observed to
beneficially effect oxidative stress in the human colonic
mucosa [43] and to induce immune-modulatory effects
[44]. Furthermore, a trend for increased combined con-
centrations of acetate, propionate and butyrate, which
are potentially beneficial to the host, was observed fol-
lowing AXOS-bread consumption compared to pre-
AXOS treatment.
Protein fermentation is considered to be a non-
beneficial process within the colon [45]. Following
AXOS-bread consumption, a trend for reduced iso-
valerate and reduced combined iso-butyrate, iso-valerate,
valerate and caproate concentrations was observed
(Table 4), which can therefore be viewed as a potentially
positive effect as these organic acids are associated with
protein fermentation [45]. This potentially beneficial
modulation of fermentation of AXOS observed through
VFA changes has been supported by previous research
in vitro [22], within rats [27] and in humans [26]. It was
therefore concluded that the AXOS-breads led to poten-
tial benefits following consumption.
Selective stimulation of indigenous beneficial gut genera
is characteristic of a prebiotic [46]. Some potentially bene-
ficial micro-organisms including Lactobacillus paracasei,
Bifidobacterium adolescentis and Bifidobacterium bifidum











b 1.44 ±0.78 1.37 ±0.76 1.39 ±0.71 1.39 ±0.79
0.10 ±0.17 0.13 ±0.20 0.18 ±0.37 0.10 ±0.17
0.17 ±0.23 0.19 ±0.27 0.25 ±0.40 0.19 ±0.23
0.49 ±0.49 0.53 ±0.53 0.51 ±0.52 0.40 ±0.48
0.01 ±0.18 0.01 ±0.19 0.02 ±0.14 0.00 ±0.13
−0.01 ±0.07 −0.01 ±0.14 −0.01 ±0.17 −0.01 ±0.08
b −0.01 ±0.21 −0.03 ±0.25 −0.03 ±0.18 −0.03 ±0.13
−0.03 ±0.26 0.04 ±0.24 0.07 ±0.25 0.05 ±0.12
3.54 ±0.92 3.73 ±0.85 3.69 ±0.98 3.51 ±0.85
er scores at different time points.
Table 6 Volunteer typical daily dietary intake whilst consuming the placebo and treatment bread products
Calories Protein Fat Carbohydrate Fibre Non starch polysaccharides Iron
(kcal) (g) (g) (g) (g) (g) (mg)
placebo 1796.0 68.1 53.8 227.5 19.8 14.9 12.9
treatment ±726.1 ±31.2 ±25.2 ±110.5 ±7.9 ±6.0 ±8.5
AXOS 1900.3 73.6 64.1 227.2 18.9 14.4 11.2
treatment ±767.5 ±53.0 ±27.4 ±127.3 ±5.7 ±4.3 ±3.9
(Average consumption from 4 consecutive days).
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play a role in stimulating Lactobacillus and Bifidobacter-
ium [50]. Moreover in research conducted by Cloetens
et al. (2010) [24], AXOS (10 g/d) produced by partial en-
zymic hydrolysis of wheat AX led to a significant Bifido-
bacterium increase. Therefore, in the current study
increases in numbers of faecal Lactobacillus and Bifido-
bacterium were expected. However, it was observed that
levels of Bifidobacterium increased significantly from
baseline following consumption of the control white
breads (Table 3). It has previously been noted that white
flour can be rich in fructans (up to 2.8%, [51]), and are
largely available for fermentation in the large intestine [3]
therefore it is likely that within the control white bread,
with 180 g consumed daily, were sufficient fructans to
have an effect on the faecal microbiota. The fructan con-
tent of rye flour has been observed to be as high as 4.5%
[52]. The lack of observed bifidogenic effect, following
consumption of the active breads, could therefore be at-
tributable to the naturally occurring fructans within all
bread products, thus masking any AXOS related effects.
In a prebiotic dose related study [53], it was observed that
a 10 g dose of galactooligosaccharide did not give rise to
an enhanced bifidogenic effect when compared to a 5 g
dose, it was therefore considered that above this threshold,
the prebiotic dose did not determine the prebiotic effect.
In terms of the current study this could explain that, al-
though additionally 2.2 g AXOS were available within the
treatment AXOS-bread, the required prebiotic dose for
bifidogenicy had already been achieved in the control and
placebo breads; thus any added effect was not apparent.
The bacteria numbers in the Lactobacillus – Entero-
coccus group were observed to significantly increase fol-
lowing the consumption of the placebo and AXOS-
breads compared to pre-treatment breads (Table 3). Both
of these breads were rye based, therefore it would seem
that rye was influencing the microbiota. This has been
supported by the use of rye grains commercially with
lactobacilli for the production of sourdough [54,55]. This
therefore indicates that rye may be considered as an ap-
propriate substrate for lactobacilli.
Consumption of the placebo breads led to significant
increases in numbers of bacteria in the E. rectale group,
the Roseburia and the Faecalibacterium prausnitziicluster compared to the pre-placebo treatment (Table 3).
This was expected as AX, which would be found
naturally occurring in the rye flour, is known to be non-
digestible [56] and also stimulates the growth of organ-
isms that possess microbial endoxylanase enzymes, such
as bacteria within E. rectale, Roseburia groups [57] and
Faecalibacterium prausnitzii. In previous human studies
on AXOS, bacteria in the E. rectale group have not been
stimulated following 10 g AXOS [24], thus this lower
dose was not expected to stimulate growth of these
microorganisms. Futhermore, Roseburia growth was not
stimulated in vitro by AXOS [58], thus the AXOS bread
may not be expected to stimulate growth of such micro-
organisms [59]. More research into this area would be
required to determine this.
AXOS-breads were stimulatory to the microbiota, as
observed through a significant increase in total bacteria
compared to pre-AXOS treatment (Table 3). Previous
intervention studies with a high dose (10 g/d) fructooli-
gosaccharides have led to similar results [60]. An in-
crease in the total bacteria numbers indicates that the
AXOS breads have an impact on the microbiota. The
butyrogenic effects then observed could relate to the dir-
ect activities of bacteria that have been stimulated, or
from a cross feeding network taking place within the
microbiota components [61] (Belenguer et al., 2006).
There was no direct increase of bacteria within the E.
rectale, Roseburia and F. prausnitzii groups which con-
tain some known butyrate producers, however there are
many other bacteria able to produce butyrate within the
microbiota through both cross-feeding networks and
also direct stimulation [62] (Louis and Flint 2007). An
increase in butyrate is considered to be a beneficial ef-
fect to the host, therefore the AXOS breads lead to this
endpoint, whilst the placebo breads did not.
Bacteroides constitutes a large proportion of the
healthy adult gastrointestinal tract, that have an ability
to adapt well to limited substrate availability [63]. In the
current study, a significant increase in numbers of
Bacteroides – Prevotella was observed following inter-
vention with AXOS and placebo breads. This is in agree-
ment with previous findings where both AXOS and AX
have been observed to increase levels of Bacteroides spp.
[19,59]. Bacteroides can grow on carbohydrates or on
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teroides are considered detrimental [64], whereas sac-
charolytic are not, because they produce potentially
beneficial VFA [65]. In the current study as there is
more carbohydrate likely to persist to the large intestine
following the AXOS and placebo treatments, these
changes are likely to be positive.
It has recently been observed that probiotics can lead
to increased salivary secretory IgA levels [27]. In the
current study, no changes in salivary sIgA were observed
(Table 6). It is worth noting that sIgA has been seen to
be elevated following a stressful work-session [66], and
examination periods [67]. Furthermore, sIgA concentra-
tions have declined in athletes following vigorous
exercise [68]. Therefore, there are many other para-
meters that may be impacting on salivary sIgA results.
In situ enrichment of AXOS in breads provides an
enhanced approach to straightforward fortification. This
process utilises naturally occurring AX – furthermore
xylanases are already used within the baking industry.
The production of these breads may be subject to some
variations, e.g. as rye and wheat composition may vary
amid intrinsic and extrinsic factors. However, providing
the level of AX within the grain is in excess of 2%, ac-
ceptable levels of AXOS generation would still be pos-
sible [18]. Therefore, it is unlikely that changes in grain
will pose a problem in production of AXOS enriched
breads.
Whilst shifts in microbial groups that are generally
considered to be of benefit (bifidobacteria, lactobacilli)
to the host were not observed following AXOS con-
sumption, there were changes in the fermentation char-
acteristics observed in terms of increased butyrate
production and a trend for less protein fermentation
markers. These results are important within a human
population as similar shifts have been observed in
animal studies and in vitro. Furthermore, the effect of
such doses on the microbial community within humans
has not been tested in such a population and whilst a
(typically) beneficial bacterial shift could not be directly
observed a fermentation shift showing positive potential
was observed. This was not observed with the placebo
products, therefore, although fermentation of the pla-
cebo was apparent, additional benefits from consump-
tion of the AXOS breads – in terms of a fermentation
shift are evident.
Conclusions
AXOS-enriched breads were well tolerated and gave rise
to a butyrogenic effect, which is of potential benefit to
the consumer. Furthermore, a trend for reduced indica-
tors of protein fermentation, with increased saccharoly-
tic fermentation end products also suggests a beneficial
shift in activities of bacteria. AXOS containing breadsenabled enhanced bifidobacterial numbers that existed
following the control bread treatment to be maintained.
It is likely that a high level of bifidobacteria, following
control bread consumption contributed to the stable
population seen during the consumption of placebo or
AXOS-breads, thus further bifidogenic effects of the
treatment breads could not be elucidated. An increase in
total bacteria following consumption of AXOS-bread
showed them to be stimulatory to the faecal microbiota;
furthermore both AXOS and placebo breads led to
increases in the potentially beneficial lactobacilli group.
The effects on fermentation end-products, that were not
observed following the placebo breads, indicate that
AXOS-bread consumption elicited a potentially benefi-
cial shift in fermentation characteristics.
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